Cancer Family
Leukemia
CI-CAN-00000215Explore in graph →
HematologicTop-level1,769 active trials42 approved drugs708 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000215Explore in graph →
Clinical trials
8,439 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,350)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01593696 | Anti-CD19 White Blood Cells for Children and Young Adults With B Cell Leukemia or Lymphoma | completed | Phase 1 | 53 | National Cancer Institute (NCI)NIH | 1 | Aug 31, 2020 | clinicaltrials |
| NCT01296932 | BI836826 Dose Escalation in Relapsed Chronic Lymphocytic Leukaemia (CLL) | completed | Phase 1 | 37 | Boehringer IngelheimINDUSTRY | 3 | Aug 20, 2020 | clinicaltrials |
| NCT02222688 |
| UC-961 (Cirmtuzumab) in Relapsed or Refractory Chronic Lymphocytic Leukemia |
| completed |
| Phase 1 |
| 26 |
| Thomas KippsOTHER |
| 1 |
| Aug 13, 2020 |
| clinicaltrials |
| NCT01885897 | IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic SCT | completed | Phase 1 / Phase 2 | 33 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Aug 12, 2020 | clinicaltrials |
| NCT00946647 | A Phase Ib/IIb, Open-label, Multi-center, Study of Oral Panobinostat Administered With 5-Azacitidine (in Adult Patients With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML). | completed | Phase 1 / Phase 2 | 113 | Novartis PharmaceuticalsINDUSTRY | 14 | Aug 4, 2020 | clinicaltrials |
| NCT00064233 | BMS-354825 in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Is Resistant to Imatinib Mesylate | completed | Phase 1 | 42 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Aug 3, 2020 | clinicaltrials |
| NCT00054236 | Combination Chemotherapy Followed By Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Severe Aplastic Anemia | completed | Phase 1 | 55 | Case Comprehensive Cancer CenterOTHER | 1 | Jul 27, 2020 | clinicaltrials |
| NCT01866839 | Preventing Stem Cell Transplant Complications With a Blood Separator Machine | completed | Phase 1 / Phase 2 | 41 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Jul 21, 2020 | clinicaltrials |
| NCT02273102 | Study of TCP-ATRA for Adult Patients With AML and MDS(TCP-ATRA) | completed | Phase 1 | 17 | University of MiamiOTHER | 1 | Jul 21, 2020 | clinicaltrials |
| NCT02405338 | DC Vaccination for Post-remission Therapy in AML | completed | Phase 1 / Phase 2 | 20 | Medigene AGINDUSTRY | 1 | Jul 7, 2020 | clinicaltrials |
| NCT03125239 | Combination Merestinib and LY2874455 for Patients With Relapsed or Refractory Acute Myeloid Leukemia | completed | Phase 1 | 16 | Jacqueline Garcia, MDOTHER | 1 | Jun 30, 2020 | clinicaltrials |
| NCT01269385 | Imprime PGG, Alemtuzumab, and Rituximab in Treating Patients With High Risk Chronic Lymphocytic Leukemia | completed | Phase 1 / Phase 2 | 22 | Mayo ClinicOTHER | 1 | Jun 23, 2020 | clinicaltrials |
| NCT02835729 | A Study of Indoximod in Combination With (7+3) Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia | completed | Phase 1 | 54 | NewLink Genetics CorporationINDUSTRY | 1 | Jun 4, 2020 | clinicaltrials |
| NCT01159028 | Clinical Trial of BP1001 (L-Grb-2 Antisense Oligonucleotide) in CML, AML, ALL & MDS | completed | Phase 1 | 60 | Bio-Path Holdings, Inc.INDUSTRY | 1 | May 28, 2020 | clinicaltrials |
| NCT02779283 | Personalized Kinase Inhibitor Therapy Combined With Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia | completed | Phase 1 | 7 | OHSU Knight Cancer InstituteOTHER | 1 | May 26, 2020 | clinicaltrials |
| NCT03661515 | Selinexor (KPT-330) Plus FLAG-Ida for the Treatment of Relapsing/Refractory AML(FLAGINEXOR) | completed | Phase 1 | 16 | PETHEMA FoundationOTHER | 1 | May 20, 2020 | clinicaltrials |
| NCT01839240 | Azacitidine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With High-Risk Acute Myeloid Leukemia | completed | Phase 1 | 50 | University of ChicagoOTHER | 1 | May 15, 2020 | clinicaltrials |
| NCT02223052 | Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies | completed | Phase 1 | 89 | CelgeneINDUSTRY | 1 | May 12, 2020 | clinicaltrials |
| NCT00462761 | A Phase I Study of AC220 in Patients With Relapsed/Refractory Acute Myeloid Leukemia Regardless of FLT3 Status | completed | Phase 1 | 76 | Daiichi SankyoINDUSTRY | 2 | May 11, 2020 | clinicaltrials |
| NCT02316197 | Clinical Phase I Study Investigating MSC2490484A, an Inhibitor of a DNA-dependent Protein Kinase, in Advanced Solid Tumors or Chronic Lymphocytic Leukemia | completed | Phase 1 | 31 | Merck KGaA, Darmstadt, GermanyINDUSTRY | 3 | Apr 28, 2020 | clinicaltrials |
| NCT02912676 | Thiopurine EnhAnced Maintenance Therapy(TEAM) | completed | Phase 1 / Phase 2 | 30 | Kjeld SchmiegelowOTHER | 1 | Apr 15, 2020 | clinicaltrials |
| NCT01830777 | Brentuximab Vedotin + Re-induction Chemotherapy for AML | completed | Phase 1 | 22 | Massachusetts General HospitalOTHER | 1 | Apr 14, 2020 | clinicaltrials |
| NCT02891590 | Safety, Tolerability and PK of BTK Inhibitor DTRMWXHS-12 in Patients With B-Cell Lymphomas | completed | Phase 1 | 13 | Zhejiang DTRM BiopharmaINDUSTRY | 1 | Apr 14, 2020 | clinicaltrials |
| NCT00428233 | Banking of Chronic Lymphocytic Leukemia Tumor Cells for Vaccine Generation | completed | Phase 1 | 65 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 8, 2020 | clinicaltrials |
| NCT02573363 | Selinexor With Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia | completed | Phase 1 | 25 | University of ChicagoOTHER | 1 | Apr 8, 2020 | clinicaltrials |
| NCT02530476 | Phase I/II, Study of Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) + Sorafenib in Acute Myeloid Leukemia | completed | Phase 1 / Phase 2 | 17 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 31, 2020 | clinicaltrials |
| NCT02212561 | Selinexor With Fludarabine and Cytarabine for Treatment of Refractory or Relapsed Leukemia or Myelodysplastic Syndrome | completed | Phase 1 | 19 | St. Jude Children's Research HospitalOTHER | 1 | Mar 26, 2020 | clinicaltrials |
| NCT01626495 | Phase I/IIA Study of CART19 Cells for Patients With Chemotherapy Resistant or Refractory CD19+ Leukemia and Lymphoma(Pedi CART19) | completed | Phase 1 / Phase 2 | 73 | University of PennsylvaniaOTHER | 1 | Mar 23, 2020 | clinicaltrials |
| NCT02011945 | A Phase 1B Study to Investigate the Safety and Preliminary Efficacy for the Combination of Dasatinib Plus Nivolumab in Patients With Chronic Myeloid Leukemia | completed | Phase 1 | 35 | Bristol-Myers SquibbINDUSTRY | 7 | Mar 18, 2020 | clinicaltrials |
| NCT02921061 | Decitabine With GCLAM for Adults With Newly Diagnosed, Relapsed, or Refractory AML or High-Risk MDS | completed | Phase 1 / Phase 2 | 28 | Fred Hutchinson Cancer CenterOTHER | 1 | Mar 17, 2020 | clinicaltrials |
| NCT02416908 | Study of CLAG + Selinexor in Relapsed or Refractory Acute Myeloid Leukemia | completed | Phase 1 / Phase 2 | 40 | Washington University School of MedicineOTHER | 1 | Mar 13, 2020 | clinicaltrials |
| NCT02892318 | A Study Evaluating the Safety and Pharmacology of Atezolizumab Administered in Combination With Immunomodulatory Agents in Participants With Acute Myeloid Leukemia (AML) | completed | Phase 1 | 40 | Hoffmann-La RocheINDUSTRY | 1 | Mar 13, 2020 | clinicaltrials |
| NCT00918333 | Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma | completed | Phase 1 / Phase 2 | 124 | Mayo ClinicOTHER | 1 | Mar 10, 2020 | clinicaltrials |
| NCT02316964 | Decitabine, Donor Natural Killer Cells, and Aldesleukin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | completed | Phase 1 | 8 | Sumithira VasuOTHER | 1 | Mar 9, 2020 | clinicaltrials |
| NCT01460498 | Azacitidine (AZA) in Minimal Residual Disease (MRD) Chronic Myeloid Leukemia (CML) | completed | Phase 1 | 3 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 5, 2020 | clinicaltrials |
| NCT01814826 | Study of MLN4924 Plus Azacitidine in Treatment-naive Participants With Acute Myelogenous Leukemia (AML) Who Are 60 Years or Older | completed | Phase 1 | 64 | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | Mar 3, 2020 | clinicaltrials |
| NCT01349049 | Phase 1/2 Safety and Efficacy of PLX3397 in Adults With Relapsed or Refractory Acute Myeloid Leukemia (AML) | completed | Phase 1 / Phase 2 | 90 | Daiichi SankyoINDUSTRY | 1 | Mar 2, 2020 | clinicaltrials |
| NCT00498316 | Cord Blood Expansion on Mesenchymal Stem Cells | completed | Phase 1 | 98 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 28, 2020 | clinicaltrials |
| NCT02546284 | Study of Lenzilumab in Previously Treated Patients With Chronic Myelomonocytic Leukemia (CMML) | completed | Phase 1 | 15 | Humanigen, Inc.INDUSTRY | 1 | Feb 28, 2020 | clinicaltrials |
| NCT03106428 | A Multiple Ascending Dose Study of MEDI7247 in Patients With Selected Relapsed/Refractory Hematological Malignancies | completed | Phase 1 | 67 | MedImmune LLCINDUSTRY | 3 | Feb 28, 2020 | clinicaltrials |
| NCT00783653 | Clinical Study of SU 11248 (Sutent) Combined With Standard Chemotherapy in Patients With FLT3 Mutated AML Over 60 Years | completed | Phase 1 / Phase 2 | 22 | Universitätsklinikum Hamburg-EppendorfOTHER | 1 | Feb 25, 2020 | clinicaltrials |
| NCT00918723 | Vorinostat, Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | completed | Phase 1 / Phase 2 | 40 | Fred Hutchinson Cancer CenterOTHER | 1 | Feb 25, 2020 | clinicaltrials |
| NCT01289457 | Clofarabine, Idarubicin, and Cytarabine (CIA) Versus Fludarabine, Idarubicin, and Cytarabine (FLAI) in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome | completed | Phase 1 / Phase 2 | 282 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 24, 2020 | clinicaltrials |
| NCT01752426 | Pilot Study to Determine Effects of the Btk Inhibitor PCI-32765 on Leukemia Cell Kinetics and Trafficking, Using Heavy Water Labeling in Subjects With CLL and SLL | completed | Phase 1 / Phase 2 | 30 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 24, 2020 | clinicaltrials |
| NCT00440726 | Bortezomib With Chemotherapy for Relapsed Pediatric Acute Lymphoblastic Leukemia (ALL) | completed | Phase 1 / Phase 2 | 31 | Therapeutic Advances in Childhood Leukemia ConsortiumOTHER | 4 | Feb 19, 2020 | clinicaltrials |
| NCT01094860 | Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of Nelarabine in Patients With Relapsed/Refractory Lymphoid Malignancies | completed | Phase 1 | 29 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 11, 2020 | clinicaltrials |
| NCT00068718 | Donor Lymphocyte Infusion in Treating Patients With Persistent, Relapsed, or Progressing Cancer After Donor Hematopoietic Cell Transplant | completed | Phase 1 / Phase 2 | 35 | Fred Hutchinson Cancer CenterOTHER | 3 | Jan 31, 2020 | clinicaltrials |
| NCT00789776 | Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation, and Donor Bone Marrow Transplant Followed by Donor Natural Killer Cell Therapy, Mycophenolate Mofetil, and Tacrolimus in Treating Patients With Hematologic Cancer | completed | Phase 1 / Phase 2 | 41 | Fred Hutchinson Cancer CenterOTHER | 1 | Jan 31, 2020 | clinicaltrials |
| NCT00005803 | Autologous Stem Cell Transplant Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoma | completed | Phase 1 / Phase 2 | 76 | Fred Hutchinson Cancer CenterOTHER | 2 | Jan 29, 2020 | clinicaltrials |
| NCT00558675 | A Phase I/II Study of Mis-Matched Immune Cells (AlloStim) in Patients With Advanced Hematological Malignancy | completed | Phase 1 / Phase 2 | 6 | Mirror Biologics, Inc.INDUSTRY | 1 | Jan 22, 2020 | clinicaltrials |
Data updated 23 days agoSource updated Aug 31, 2020source: clinicaltrials